Avidity Biosciences, Inc.

Quick facts

Phase 3 pipeline

• AOC 1001 (del-desiran) · Rare genetic disease
  AOC 1001 is an antisense oligonucleotide conjugate that targets and reduces expression of a disease-causing gene through a tissue-directed delivery approach.
• AOC-1020
• Del-desiran (AOC 1001) · Cardiovascular
  Del-desiran is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III) to lower triglycerides and improve lipid metabolism.

Phase 2 pipeline

• AOC 1001
• AOC 1044 · Immunology
  AOC 1044 is an investigational antisense oligonucleotide.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Avidity Biosciences, Inc. portfolio CI brief
• Avidity Biosciences, Inc. pipeline updates RSS